Fasting Study of Mercaptopurine 50 mg and Purinethol® Tablets 50 mg

Mylan

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: Purinethol® Tablets 50 mg

Drug: Mercaptopurine 50 mg

Study type

Interventional

Funder types

Industry

Identifiers

NCT00648336

MERC-0360

Details and patient eligibility

About

The objective of this study was to investigate the bioequivalence of Mylan's mercaptopurine 50 mg tablets to Gate's Purinethol® 50 mg tablets following a single, oral 50 mg (1 x 50 mg) dose administered under fasting conditions.

Enrollment

60 patients

Sex

Male

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Age: 18 years and older.
Sex: Male
Volunteers are to be sterile (documentation required) or during the course of the study, from study screen until 3 months after study exit, non-sterile male volunteers must use a spermicide-containing barrier method of contraception to prevent the pregnancy of their sexual partner. This advice should be documented in the informed consent form.
Weight: At least 60 kg (132 lbs.) and within 15% of Ideal Body Weight (IBW), as referenced by the Table of ""Desirable Weights of Adults"" Metropolitan Life Insurance Company, 1999 (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).
All subjects should be judged normal and healthy during a pre-study medical evaluation (physical examination, laboratory evaluation, 12-lead ECG, hepatitis B and hepatitis C tests, HIV test, and urine drug screen including amphetamine, barbiturates, benzodiazepine, cannabinoid, cocaine, opiate screen, phencyclidine, and methadone) performed within 14 days of the initial dose of study medication.

Exclusion criteria

Institutionalized subjects will not be used.
Social Habits:
1. Use of any tobacco products within 1 year of the start of the study.
2. Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage within the 48 hours prior to the initial dose of study medication.
3. Ingestion of any vitamin or herbal supplements within 7 days prior to the initial dose of the study medication.
4. Any recent, significant change in dietary or exercise habits.
5. History of drug and/or alcohol abuse within 1 year of the start of the study.
6. A positive result for any drug in the urine drug screen.
Medications:
1. Use of any medication within the 14 days prior to the initial dose of study medication.
2. Use of any medication known to alter hepatic enzyme activity within 28 days prior to the initial dose of study medication.
3. Use of allopurinol or aminosalicylates (e.g. olsalazine, mesalamine, sulfasalazine) within 3 months of the start of the study.
Diseases:
1. History of any significant chronic disease and/or hepatitis.
2. Acute illness at the time of either the pre-study medical evaluation or dosing.
3. A positive HIV, hepatitis B, or hepatitis C test.
Abnormal and clinically significant laboratory test results:
1. Clinically significant deviation from the Guide to Clinically Relevant Abnormalities (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).
2. Abnormal and clinically relevant ECG tracing.
3. Abnormal liver function tests (i.e. ALT (SGPT), AST (SGOT), alkaline phosphatase, bilirubin).
Donation or loss of a significant volume of blood or plasma (> 450 mL) within 28 days prior to the initial dose of study medication.
Subjects who have received an investigational drug within 30 days prior to the initial dose of study medication.
Allergy or hypersensitivity to mercaptopurine or other related products.
History of difficulties in swallowing, or any gastrointestinal disease which could affect the drug absorption.
Consumption of grapefruit or grapefruit containing products within 7 days of drug administration.
Family history of a deficiency in the enzyme thiopurine methyltransferase.